Determination of 3-methoxy-4-hydroxyphenylpyruvic acid, 3,4-dihydroxyphenylethylene glycol, and 3,4-dihydroxyphenylmandelic acid in urine by mass fragmentography, with use of deuterium-labeled internal standards. 1978

F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries

We report the determination of 3-methoxy-4-hydroxyphenylpyruvic acid, 3,4-dihydroxyphenylmandelic acid, and 3,4-dihydroxyphenylethylene glycol in urine, by use of gas chromatography/mass spectrometry in combination with a simple purification method and deuterium-labeled internal standards. Normal excretion values in terms of creatinine, expressed as a function of age, are given, together with results obtained for patients with neuroblastoma, pheochromocytoma, or parkinsonism treated with L-DOPA + peripheral decarboxylase inhibitor, and for a patient receiving dopamine. We were unable to identify 3, 4-dihydroxyphenyllactic acid in urine. The results obtained and their relation to other catecholamine metabolites and catecholamine-precursor metabolites in urine are discussed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008333 Mandelic Acids Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid). Acids, Mandelic
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D008734 Methoxyhydroxyphenylglycol Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover. Hydroxymethoxyphenylglycol,MHPG,MOPEG,Vanylglycol,4-Hydroxy-3-methoxyphenylethylene Glycol,4-Hydroxy-3-methoxyphenylethyleneglycol,4-Hydroxy-3-methoxyphenylglycol,Methoxyhydroxyphenylglycol, (+)-Isomer,Methoxyhydroxyphenylglycol, (+-)-Isomer,Methoxyhydroxyphenylglycol, (-)-Isomer,4 Hydroxy 3 methoxyphenylethylene Glycol,4 Hydroxy 3 methoxyphenylethyleneglycol,4 Hydroxy 3 methoxyphenylglycol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010667 Phenylpyruvic Acids A group of compounds that are derivatives of phenylpyruvic acid which has the general formula C6H5CH2COCOOH, and is a metabolite of phenylalanine. (From Dorland, 28th ed) Acids, Phenylpyruvic

Related Publications

F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
November 1980, Analytical biochemistry,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
February 1981, Annales pharmaceutiques francaises,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
September 1974, Biochemical medicine,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
June 1981, Biomedical mass spectrometry,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
July 1978, Chemical & pharmaceutical bulletin,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
January 1984, Journal of pharmaceutical and biomedical analysis,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
January 1987, Journal of chromatography,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
March 1962, Clinica chimica acta; international journal of clinical chemistry,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
March 1978, Journal of chromatography,
F A Muskiet, and D C Fremouw-Ottevangers, and G T Nagel, and B G Wolthers, and J A de Vries
December 1973, Journal of chromatography,
Copied contents to your clipboard!